While there are several potential targets under investigation, one of the most promising is LAG-3, which is a co-inhibitory receptor that suppresses T-cell activation and cytokine secretion.4,5 Approved in 2022 for the treatment of metastatic or unresectable melanoma in combination with nivolumab, relatlimab combined with nivolumab resulted in a superior progression-free survival (PFS) of 10.1 months, compared to 4.6 months for nivolumab monotherapy.5 In this review, we aim at providing an overview of LAG-3 immune checkpoint blockade, which extended the immunotherapy landscape in melanoma. Here, LAG3 is linked to melanoma.